Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
Infect Dis Ther ; 11(4): 1327-1341, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35767219

ABSTRACT

Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 (HIV-1). To evaluate the efficacy and safety of an intensified anti-tubercular regimen and an anti-inflammatory treatment, the INTENSE-TBM project includes a phase III randomised clinical trial (TBM-RCT) in four countries in sub-Saharan Africa (SSA). Within this framework, we designed a comprehensive capacity-building work package ensuring all centres had, or would acquire, the ability to conduct the TBM-RCT and developing a network of skilled researchers, clinical centres and microbiology laboratories. Here, we describe these activities, identify strengths/challenges and share tools adaptable to other projects, particularly in low- and lower-middle income countries with heterogeneous settings and during the coronavirus disease 2019 (COVID-19) pandemic. Despite major challenges, TBM-RCT initiation was achieved in all sites, promoting enhanced local healthcare systems and encouraging further clinical research in SSA. In terms of certified trainings, the achievement levels were 95% (124/131) for good clinical practice, 91% (39/43) for good clinical laboratory practice and 91% (48/53) for infection prevention and control. Platform-based research, developed as part of capacity-building activities for specific projects, may be a valuable tool in fighting future infectious diseases and in developing high-level research in Africa.


The INTENSE-TBM project aimed to design a comprehensive work-package on capacity building, ensuring all centres would acquire the ability to conduct a phase III randomised clinical trial on TBM in sub-Saharan Africa, to reduce tuberculous meningitis mortality and morbidity in patients with/without HIV-1 co-infection. Therefore, the INTENSE-TBM project is an example of how an international clinical research consortium can provide opportunities to enhance local capacity building and promote centres without previous experience in clinical research. This article provides practical approaches for implementing effective capacity-building programmes. We highlight how to overcome limitations imposed by the COVID-19 pandemic to successfully complete clinics, laboratory set-ups and personnel training, so as to optimise resources and empower African institutions on a local level. At the same time, our experience shows how capacity-building programmes can deliver long-lasting impact that extends beyond the original aims of the project (e.g. HIV and TB), and support local health systems in fighting other infectious disease (e.g. COVID-19). Research projects in low- and lower-middle income countries with heterogeneous settings could stand to benefit the most.

2.
Int J Infect Dis ; 69: 20-25, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29408360

ABSTRACT

OBJECTIVE: To evaluate the feasibility of the implementation of a commercial rapid molecular diagnostic test (Xpert MTB/RIF) for the routine diagnosis of smear-negative or extrapulmonary tuberculosis (TB) and its diagnostic accuracy, and to assess HIV prevalence in a real-life setting in Madagascar. This study was set in a tertiary care hospital in Madagascar. METHODS: A prospective cohort study was conducted of all consecutive cases with suspected smear-negative and/or extrapulmonary TB over a 2-year period. Cases were classified as proven, probable, or possible TB cases, or as having an alternative diagnosis. RESULTS: Of the 363 patients included, 183 (50.4%) had suspected smear-negative pulmonary TB and 180 (49.6%) had suspected extrapulmonary TB. For proven cases, the sensitivity, specificity, positive and negative predictive values of Xpert MTB/RIF were 82.4%, 98.8%, 98.3%, and 86.6%, respectively; for proven and probable cases grouped together, these values were 65%, 98.8%, 98.5%, and 64%, respectively. The diagnostic accuracy was slightly lower for extrapulmonary TB compared to smear-negative pulmonary TB. The prevalence of HIV infection was 12.1%, but almost half of these cases did not have TB (alternative diagnosis group). CONCLUSIONS: The implementation of a rapid diagnosis programme for TB in a resource-poor setting is feasible. The performance of the Xpert-MTB/RIF was remarkable in this difficult-to-diagnose population. HIV prevalence in this study was much higher than the prevalence reported in the general population in Madagascar, in patients with TB and patients with conditions other than TB.


Subject(s)
Antitubercular Agents/therapeutic use , Molecular Diagnostic Techniques , Sputum/microbiology , Tuberculosis, Pulmonary/microbiology , Adult , Feasibility Studies , Female , Humans , Madagascar , Male , Microbial Sensitivity Tests , Middle Aged , Mycobacterium tuberculosis/genetics , Prevalence , Prospective Studies , Rifampin/therapeutic use , Sensitivity and Specificity , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/genetics
3.
Revue Médicale de Madagascar ; 1(3): 69-70, 2011.
Article in French | AIM (Africa) | ID: biblio-1269366

ABSTRACT

Le virus d'Epstein-Barr est responsable de la mononucleose infectieuse. Il peut induire la formation d'anticoagulants circulants sans qu'apparaissent obligatoirement des manifestations thrombotiques. Nous rapportons le cas d'un jeune patient hospitalise pour une thrombose portale revelee par des manifestations douloureuses abdominales. La recherche d'anticoagulant circulant de type lupique dans le sang etait positive. Le bilan de thrombophilie s'averait negative. Nous n'avons pas retrouve de cas similaire dans la litterature. Le role des anticoagulants circulants semble etre primordial dans la constitution de cette obstruction de la veine porte. Une infection virale peut etre a l'origine de manifestations thrombotiques intra-abdominales par le biais de l'action thrombogene des anticoagulants circulants in vivo


Subject(s)
Anticoagulants , Case Reports , Epstein-Barr Virus Infections , Venous Thrombosis
SELECTION OF CITATIONS
SEARCH DETAIL
...